Patents by Inventor Toshihiko Fujiwara

Toshihiko Fujiwara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020111373
    Abstract: The present invention concerns the hydrochloride of the compound (5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidin-2,4-dione) of the following structure (I) which exhibits an excellent hypoglycemic activity and the like.
    Type: Application
    Filed: November 21, 2001
    Publication date: August 15, 2002
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takashi Fujita, Toshihiko Fujiwara, Takashi Izumi
  • Patent number: 6432993
    Abstract: Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: wherein R1 is a group of the formula (II) or (III): R4 is a substituted phenyl or a pyridyl which may have a substituent. R5 is hydrogen or the like. R6 is hydrogen, a C1-6 alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2 is hydrogen or the like. R3 is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6 alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: August 13, 2002
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Kunio Wada, Toshihiko Fujiwara
  • Patent number: 6353009
    Abstract: Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: March 5, 2002
    Assignee: Sankyo Company, Limited
    Inventors: Toshihiko Fujiwara, Koichi Iwasaki, Hiroyoshi Horikoshi
  • Publication number: 20020013308
    Abstract: A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress inhibitory effects, and is useful as a drug, particularly as a drug for the prevention or treatment of arteriosclerosis. The invention also provides a method for the treatment or prophylaxis of arteriosclerosis by administering in combination (i) at least one of said angiotensin II receptor antagonists or angiotensin converting enzyme inhibitors and (ii) one or more insulin resistance improving agents to a mammal suffering from or susceptible to arteriosclerosis.
    Type: Application
    Filed: August 21, 2001
    Publication date: January 31, 2002
    Applicant: SANKYO COMPANY LIMITED
    Inventors: Yoshio Tsujita, Toshihiko Fujiwara, Toshio Sada, Naoyuki Maeda
  • Patent number: 6150371
    Abstract: A method for preventing or treating autoimmune diseases (excluding type I diabetes) by administering an insulin resistance improving substance as an active ingredient.
    Type: Grant
    Filed: November 30, 1998
    Date of Patent: November 21, 2000
    Assignee: Sankyo Company, Limited
    Inventors: Toshihiko Fujiwara, Shinichi Kurakata, Takashi Fujita, Tsunemichi Hosokawa, Junichiro Fukushige, Hiroyoshi Horikoshi
  • Patent number: 6117893
    Abstract: Compound of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: September 12, 2000
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 6103907
    Abstract: Phenylalkylcarboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 represents an alkyl group and the like, R.sup.2 represents an alkylene group, R.sup.3 represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like),the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: August 15, 2000
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Makoto Takamura, Takashi Fujita, Toshihiko Fujiwara
  • Patent number: 5977365
    Abstract: Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrinidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidom ethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an inzeger of from 1 to 5] have hypoglycemic and anti-diabetic activities.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: November 2, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 5972959
    Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is alkylene; R.sup.3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N--R.sup.4, in which R.sup.4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): ##STR2## and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: October 26, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Takashi Fujita, Koichi Fujimoto, Takao Yoshioka, Kunio Wada, Minoru Oguchi, Toshihiko Fujiwara, Hiroyoshi Horikoshi
  • Patent number: 5962470
    Abstract: Compounds of formula (I): ##STR1## ?wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5! have hypoglycemic and anti-diabetic activities.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: October 5, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 5886014
    Abstract: Compounds of formula (I): ##STR1## ?wherein: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethlyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5!; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.
    Type: Grant
    Filed: May 31, 1996
    Date of Patent: March 23, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Kunio Wada, Minoru Oguchi, Hiroaki Yanagisawa, Koichi Fujimoto, Toshihiko Fujiwara, Hiroyoshi Horikoshi, Takao Yoshioka
  • Patent number: 5834501
    Abstract: Compounds of formula (I): ##STR1## wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidom ethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5 have hypoglycemic and anti-diabetic activities.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: November 10, 1998
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 5804590
    Abstract: Compounds of formula (I): ##STR1## where R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen or alkyl and R.sup.3 is hydrogen, alkyl or various organic groups are effective against osteoporosis at doses at which they also effectively control diabetes.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: September 8, 1998
    Assignee: Sankyo Company, Limited
    Inventors: Toshihiko Fujiwara, Masaaki Miyamoto, Hiroyoshi Horikoshi
  • Patent number: 5780490
    Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is alkylene; R.sup.3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N--R.sup.4, in which R.sup.4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): ##STR2## and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: July 14, 1998
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Takashi Fujita, Koichi Fujimoto, Takao Yoshioka, Kunio Wada, Minoru Oguchi, Toshihiko Fujiwara, Hiroyoshi Horikoshi
  • Patent number: 5753681
    Abstract: Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: May 19, 1998
    Assignee: Sankyo Company, Limited
    Inventors: Toshihiko Fujiwara, Hiroyoshi Horikoshi, Masaharu Fukami
  • Patent number: 5739345
    Abstract: Compounds of formula (I): ##STR1## ?wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5! have hypoglycemic and anti-diabetic activities. Disclosed also are intermediate compounds for the preparation of compounds of formula I.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: April 14, 1998
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 5703096
    Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is alkylene; R.sup.3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N-R.sup.4, in which R.sup.4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): ##STR2## and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.
    Type: Grant
    Filed: October 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Takashi Fujita, Koichi Fujimoto, Takao Yoshioka, Kunio Wada, Minoru Oguchi, Toshihiko Fujiwara, Hiroyoshi Horikoshi
  • Patent number: 5688823
    Abstract: Compounds of formula (I): ##STR1## Z is a group of formula (iii), (iv),: ##STR2## and salts, esters and solvates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: November 18, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Koichi Fujimoto, Takao Yoshioka, Hiroaki Yanagisawa, Toshihiko Fujiwara, Hiroyoshi Horikoshi, Minoru Oguchi, Kunio Wada
  • Patent number: 5624935
    Abstract: Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: April 29, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Takao Yoshioka, Toshihiko Fujiwara, Minoru Oguchi, Hiroaki Yanagisawa, Hiroyoshi Horikoshi, Kunio Wada, Koichi Fujimoto
  • Patent number: 5614542
    Abstract: Thiazolidine derivatives of formula (I): ##STR1## (in which: R.sup.1, R.sup.2, R.sup.4, R.sup.5 are each hydrogen or alkyl; and R.sup.3 is hydrogen, aliphatic acyl, alkoxy-carbonyl, or arylcarbonyl and pharmaceutically acceptable salts thereof are anti-hypertensive agents and are useful in the treatment of obesity-related hypertension.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 25, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Hiroyoshi Horikoshi, Toshihiko Fujiwara, Shinji Yoshioka, Hiroshi Nishino, Hiroyuki Koike, Takao Yoshioka